WASHINGTON--(BUSINESS WIRE)--The following statement was issued today by Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood in conjunction with a hearing held this morning on follow-on biologics before the Senate Health, Education, Labor and Pensions Committee:
